Table 3.

Cox regression analysis of the progression-free survival.

PFS	Univariable Analysis			Multiple Analysis
	p-Value	HR	95% CI	p-Value	HR	95% CI
pIBA1	0.60	1.00	0.99–1.00
pVEGF	0.35	0.90	0.73–1.12
pCXCL2	0.29	1.08	0.93–1.26
pIL8	0.60	0.82	0.39–1.72
pvessel count	0.48	1.01	0.99–1.02
pvessel area	0.49	1114.81	0.00–6.63 × 1011
pCXCR2+ vessels	0.25	0.99	0.98–1.01
pCXCR2+ vessel area	0.32	0.00	0.00–4.34 × 1041
TMZ cycles	0.01	0.86	0.77–0.96	0.02	0.87	0.78–0.98
MGMT methylation	0.04	0.97	0.94–0.99	0.09	0.98	0.95–1.00

p = primary tumor; TMZ = temozolomide; HR = Hazard Ratio; 95% CI = 95% confidence interval.